首页 | 本学科首页   官方微博 | 高级检索  
     

石斛夜光丸联合聚乙二醇滴眼液治疗干眼的临床研究
引用本文:王佳娣,刘悦,曹丛红,宗贝婷,姚靖. 石斛夜光丸联合聚乙二醇滴眼液治疗干眼的临床研究[J]. 现代药物与临床, 2024, 39(2): 432-437
作者姓名:王佳娣  刘悦  曹丛红  宗贝婷  姚靖
作者单位:黑龙江中医药大学附属第一医院 眼科, 黑龙江 哈尔滨 150001
基金项目:国家自然科学基金面上项目(81973908);黑龙江省中医药科研项目(ZYW2022-051、ZHY2023-126)
摘    要:目的 分析石斛夜光丸联合聚乙二醇滴眼液治疗干眼的临床疗效。方法 选取2022年6月—2023年6月黑龙江中医药大学附属第一医院收治的136例干眼患者,按随机数字表法将所有患者分为对照组和治疗组,每组各68例。对照组接受聚乙二醇滴眼液治疗,使用前摇匀,每眼1滴/次,3次/d。治疗组在对照组治疗基础上口服石斛夜光丸,1丸/次,2次/d。两组疗程4周。比较两组临床疗效、荧光素染色泪膜破裂时间(FBUT)等相关临床检查指标及眼表疾病指数(OSDI)量表、干眼相关生活质量评分问卷(DEQS)、简式抑郁–焦虑–压力量表(DASS-21)评分和泪液中转化生长因子-β2(TGF-β2)、CC趋化因子配体1(CCL1)、可溶性生长刺激表达基因2蛋白(s ST2)、白细胞介素(IL)-1β水平。结果 治疗后,治疗组总有效率是97.06%,显著高于对照组的88.24%(P<0.05)。治疗后,两组FBUT、SⅠt和泪河高度均显著增加,而FL评分均显著降低(P<0.05);治疗后,治疗组相关临床检查指标改善优于对照组(P<0.05)。治疗后,两组OSDI评分、DEQS评分和DASS-21评分...

关 键 词:石斛夜光丸  聚乙二醇滴眼液  干眼  荧光素染色泪膜破裂时间  眼表疾病指数量表评分  干眼相关生活质量评分问卷评分  转化生长因子-β2  CC趋化因子配体1
收稿时间:2023-08-16

Clinical study of Shihu Yeguang Pills combined with Polyethylene Glycol Eye Drops in treatment of dry eyes
WANG Jiadi,LIU Yue,CAO Conghong,ZONG Beiting,YAO Jing. Clinical study of Shihu Yeguang Pills combined with Polyethylene Glycol Eye Drops in treatment of dry eyes[J]. Drugs & Clinic, 2024, 39(2): 432-437
Authors:WANG Jiadi  LIU Yue  CAO Conghong  ZONG Beiting  YAO Jing
Affiliation:Department of Ophthalmology, First Affiliated Hospital of Heilongjiang University of Chinese medicine, Harbin 150001, China
Abstract:Objective To analyze the clinical efficacy of Shihu Yeguang Pills combined with Polyethylene Glycol Eye Drops in treatment of dry eyes. Methods A total of 136 patients with dry eye treated in the First Affiliated Hospital of Heilongjiang University of Chinese Medicine from June 2022 to June 2023 were selected and divided into control group and treatment group according to random number table method, with 68 cases in each group. Patients in control group were given Polyethylene Glycol Eye Drops, shook well before use, 1 drop/eye, 3 times daily. Patients in the treatment group were po administered with Shihu Yeguang Pills on the basis of the control group, 1 pill/time, twice daily. Both groups were treated for 4 weeks. The clinical efficacy, fluorescein stained tear film break time (FBUT) and other relevant clinical examination indicators, OSDI scores, DEQS scores, DASS-21 scores, TGF-β2, CCL1, sST2, and IL-1β were compared in two groups before and after treatment were compared.Results After treatment, the total effective rate of the treatment group was 97.06%, which was significantly higher than that of the control group (88.24%, P< 0.05). After treatment, FBUT, SⅠt and lacrimal river height were significantly increased, while FL scores were significantly decreased in both groups (P < 0.05). After treatment, the improvement of relevant clinical examination indexes in the treatment group was better than that in the control group (P < 0.05). After treatment, OSDI score, DEQS score and DASS-21 score were significantly decreased in both groups (P < 0.05). After treatment, OSDI score, DEQS score and DASS-21 score in treatment group were significantly lower than those in control group (P < 0.05). After treatment, the levels of TGF-β2 in tears of both groups were significantly increased, but the levels of CCL1, sST2 and IL-1β in tears were significantly decreased (P< 0.05). After treatment, the improvement of TGF-β2, CCL1, sST2 and IL-1β in tears of the treatment group was better than that of control group (P < 0.05). Conclusion Shihu Yeguang Pills combined with Polyethylene Glycol Eye Drops has definite curative effects in treatment of dry eyes, and can safely and effectively control dry eye, promote the alleviation of ocular inflammation and ocular surface damage, further improve the stability of tear film and tear secretion function of patients, improve the quality of life and mental state, which is worthy of clinical promotion and application.
Keywords:Shihu Yeguang Pills  Polyethylene Glycol Eye Drops  dry eye  FBUT  OSDI scores  DEQS scores  TGF-β2  CCL1
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号